US Patent 9067977 Peptides derivatized with A-B-C-D- and their therapeutical use
Patent 9067977 was granted and assigned to Novo Nordisk on June, 2015 by the United States Patent and Trademark Office.
All edits
The invention relates to protracted peptide derivatives such as Glucagon-Like Peptide-1 (GLP-1), exendin-4, and analogs thereof, as well as therapeutic uses thereof. The peptide derivative of the invention comprises a peptide wherein at least one amino acid residue is derivatized with A-B-C-, or A-B-C-D-. These compounds are useful in the treatment or prevention of diabetes type 2 and related diseases. The compounds are potent, have a low ratio of binding affinity to the GLP-1 receptor in the presence of high/low albumin concentrations, have long half-lives, and have a high affinity of binding to albumin, all of which is of potential relevance for the overall aim of achieving long-acting, stable and active GLP-1 derivatives with a potential for once weekly administration.
US Patent 09067977 Peptides derivatized with A-B-C-D- and their therapeutical use US Patent 9067977 Peptides derivatized with A-B-C-D- and their therapeutical use
US Patent 09067977 Peptides derivatized with A-B-C-D- and their therapeutical use
Find more entities like US Patent 9067977 Peptides derivatized with A-B-C-D- and their therapeutical use
